KAMPALA, UGANDA – April 4, 2017 – Today, the Sabin Vaccine Institute opened the 10th International Conference on Typhoid and Other Invasive Salmonelloses in Kampala, Uganda. Over the course of the three day conference, more than 300 experts from around the world have gathered to discuss new typhoid-related research, as well as how to turn this evidence into action in the fight against typhoid.

Typhoid fever, an illness caused by the bacteria Salmonella Typhi, kills an estimated 220,000 people, primarily children, each year. Currently available typhoid vaccines are underutilized in low- and middle-income countries, including many countries in Africa and Asia. Vaccines for other, nontyphoidal strains of Salmonella bacteria are not available. Typhoid is treated with antibiotics, but the recent rise of antibiotic-resistant typhoid and nontyphoidal Salmonella has increased the burden of treatment on health systems and families. There is an urgent need for new effective vaccines and policies to help prevent the disease and its transmission in communities. Preventing typhoid will minimize the need to treat this serious infection and will also reduce the danger of antibiotic resistance.

There has been significant progress in typhoid vaccine development. New typhoid conjugate vaccines offer important advantages over prior vaccines, including longer duration of protection, the ability to protect young children, and the potential for delivery with other vaccines in routine immunization of infants. Conjugate vaccines have the potential to dramatically reduce the burden of typhoid around the world and, consequently, help to prevent the occurrence of antibiotic resistance. The research shared at Sabin’s conference – the world’s only such meeting devoted to typhoid and other invasive salmonelloses – will inform discussions at the World Health Organization later this month, when experts gather to review recommendations on the use of typhoid vaccines.

“This conference comes at a pivotal moment for global action on typhoid,” said Bruce Gellin, president of Global Immunization at the Sabin Vaccine Institute. “Determining how to most effectively implement prevention efforts, particularly new vaccines, is critical to reduce the number of people – approximately 220,00 annually – dying from typhoid. To have the greatest impact, we need to review the evidence for these vaccines and consider the vaccination programs in which they will be delivered. The discussions and debates over the next three days at this conference will help the researchers, policy makers and advocates meet the urgent need for prevention and control.”

During the conference, participants will present new research, promote scientific collaboration and advance a clear agenda for preventing typhoid and other invasive salmonelloses. Among the findings presented at the conference will be data from Sabin’s surveillance of enteric fever in Asia. Discussions will include updates on the global disease burden; antibiotic resistance; best practices for diagnostics and surveillance; the role of water, sanitation and hygiene practices; and strategies for prevention and control, including progress on vaccines in development -- including new typhoid conjugate vaccines.

Sabin seeks to speed the adoption of effective immunization practices by convening researchers and global health decision makers. By sharing research and best practices, conference participants are able to make better, evidence-based decisions on vaccines. The evidence presented at this conference will help lay a foundation for the effective implementation of typhoid vaccines.

For more information on the conference, see Sabin’s website.

###

About The Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit http://www.sabin.org and follow us on Twitter, @SabinVaccine.

Media Contact
Name: 
Hannah Bassett
Phone: 
+1 (202) 621-1691